|Conditional recommendation based on very-low-quality evidence; may consider adding MTX to an IL-17i if the patient had had a partial response to the existing regimen.| |
|In adult patients with active PsA despite treatment with an IL-12/23i biologic monotherapy,| |
|6. Switch to a TNFi biologic over switching to an IL-17i biologic (PICO 38)|Very low|